Equitable Trust Co. Has $1.60 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Equitable Trust Co. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 11.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,248 shares of the medical equipment provider’s stock after selling 432 shares during the period. Equitable Trust Co.’s holdings in Intuitive Surgical were worth $1,596,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ISRG. Creekmur Asset Management LLC boosted its position in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. Ridgewood Investments LLC acquired a new stake in shares of Intuitive Surgical during the 2nd quarter valued at $26,000. Delos Wealth Advisors LLC grew its position in Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares during the last quarter. Godsey & Gibb Inc. increased its holdings in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. Finally, LRI Investments LLC bought a new position in Intuitive Surgical in the first quarter valued at about $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Up 2.3 %

NASDAQ:ISRG opened at $536.45 on Friday. Intuitive Surgical, Inc. has a twelve month low of $269.49 and a twelve month high of $538.49. The company has a fifty day moving average of $493.92 and a 200-day moving average of $451.73. The firm has a market capitalization of $191.07 billion, a P/E ratio of 86.25, a P/E/G ratio of 5.07 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. On average, analysts anticipate that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 240 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $464.76, for a total value of $111,542.40. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,558,968.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, EVP Brian Edward Miller sold 2,553 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total transaction of $1,314,795.00. Following the completion of the sale, the executive vice president now owns 7,066 shares in the company, valued at approximately $3,638,990. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 240 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $464.76, for a total transaction of $111,542.40. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,558,968.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,246 shares of company stock valued at $33,839,308 in the last three months. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ISRG shares. The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a report on Friday, October 18th. Barclays upped their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Royal Bank of Canada lifted their price target on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a report on Friday, October 18th. Stifel Nicolaus increased their price objective on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a report on Friday, October 18th. Finally, JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.